| Sign In to gain access to subscriptions and/or personal tools. |
Review: Preventing diabetes in the obese: the XENDOS study and its contextDepartment of Body Composition and Metabolism, Vita Stråket 15, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden, jarl.torgerson{at}medfak.gu.se This article reviews the evidence, from both observational epidemiology and randomised clinical trials, that lifestyle modification as well as anti-diabetic drugs can reduce or delay the development of diabetes in overweight and obese patients with IGT. Particular consideration is given to the recently published XENDOS study which showed that the combination of orlistat and lifestyle changes over four years is safe and well tolerated, results in a weight loss of about six kg and reduces the risk of developing diabetes by 45% in obese IGT patients. Thus, addition of orlistat to lifestyle intervention has a greater diabetes-preventing effect than lifestyle modification alone.
Key Words: diabetes obesity prevention lifestyle drug treatment.
The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 1,
22-27 (2004) |
||||